GREY:ATBPF - Post by User
Comment by
WalkOverTheStrton Nov 18, 2023 1:25pm
185 Views
Post# 35742684
RE:RE:RE:comgrats
RE:RE:RE:comgratsMugs I don't have a high view of Dan so I look at his sales of stock as a potential indicator, a data point. If mgmt bought on the open market that would be a nice sign of confidence.
I'll call out from your list the new molecule effort is a poor strategy by mgmt. They have for five plus years spent capital on trying to advance new molecules imo at the expense of Otena. The more this company takes its limited resources/focus from PH2 to new molecules the more likely they are in miss deadlines/increasing their burn rate. This company/mgmt should focus on gettting acute to the finish line and if successful they can fund the other drugs with those revenues. It's time for them to get one drug over the finish line and reduce the degree of dilution on investors bc of these low value add early development drugs. Drugs in animal studies don't move the MC needle much if at all so I'd prefer they look at SH interests and build value thru their best chance with the limited capital they have.
- Nuance resolution
- P2 planning
- Chronic path
- new molecules
- breakthrough therapy designation
- partnnering opportunities